-
1
-
-
17044456283
-
Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients
-
Burrer R, Salmon-Ceron D, Richert S, et al.: Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J Virol 2001;75:5421-5424.
-
(2001)
J Virol
, vol.75
, pp. 5421-5424
-
-
Burrer, R.1
Salmon-Ceron, D.2
Richert, S.3
-
2
-
-
0036394419
-
Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08
-
Verrier B, Le Grand R, Ataman-Onal Y, et al.: Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol 2002;21:653-658.
-
(2002)
DNA Cell Biol
, vol.21
, pp. 653-658
-
-
Verrier, B.1
Le Grand, R.2
Ataman-Onal, Y.3
-
3
-
-
0032437454
-
The rule of non-nuclcoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
-
De Clercq E: The rule of non-nuclcoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153-179.
-
(1998)
Antiviral Res
, vol.38
, pp. 153-179
-
-
De Clercq, E.1
-
4
-
-
0032751029
-
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients
-
Villani P, Regazzi MB, Castelli F, et al.: Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999;48:712-715.
-
(1999)
Br J Clin Pharmacol
, vol.48
, pp. 712-715
-
-
Villani, P.1
Regazzi, M.B.2
Castelli, F.3
-
5
-
-
0037320996
-
Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals
-
Mallon PW, Ray J, and Cooper DA: Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 2003;26:223-227.
-
(2003)
J Clin Virol
, vol.26
, pp. 223-227
-
-
Mallon, P.W.1
Ray, J.2
Cooper, D.A.3
-
6
-
-
0035875828
-
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
-
Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
-
(2001)
AIDS
, vol.15
, pp. 71-75
-
-
Marzolini, C.1
Telenti, A.2
Decosterd, L.A.3
Greub, G.4
Biollaz, J.5
Buclin, T.6
-
7
-
-
0141532404
-
-
DuPont Pharmaceuticals: DuPont Pharmaceuticals, Herfordshire, UK
-
DuPont Pharmaceuticals: Sustiva (Efavirenz product package insert) DuPont Pharmaceuticals, Herfordshire, UK, 1999.
-
(1999)
Sustiva (Efavirenz Product Package Insert)
-
-
-
8
-
-
0029820967
-
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease
-
Bilello JA and Drusano GL: Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infect Dis 1996;173:1524-1526.
-
(1996)
J Infect Dis
, vol.173
, pp. 1524-1526
-
-
Bilello, J.A.1
Drusano, G.L.2
-
10
-
-
0034128898
-
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
-
Corbett JW, Ko SS, Rodgers JD, et al.: Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem 2000;43:2019-2030.
-
(2000)
J Med Chem
, vol.43
, pp. 2019-2030
-
-
Corbett, J.W.1
Ko, S.S.2
Rodgers, J.D.3
-
11
-
-
0028124660
-
Bicycle imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1
-
Moog C, Wick A, Le Ber P, Kirn A, and Aubenin AM: Bicycle imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res 1994;24:275-288.
-
(1994)
Antiviral Res
, vol.24
, pp. 275-288
-
-
Moog, C.1
Wick, A.2
Le Ber, P.3
Kirn, A.4
Aubenin, A.M.5
-
12
-
-
0037419657
-
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography
-
Turner ML, Reed-Walker K, King JR, and Acosla EP: Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B 2003;784:331-341.
-
(2003)
J Chromatogr B
, vol.784
, pp. 331-341
-
-
Turner, M.L.1
Reed-Walker, K.2
King, J.R.3
Acosla, E.P.4
-
13
-
-
0035025888
-
A quantitative assay for HIV DNA integration in vivo
-
Butler SM, Hansen MS, and Bushman FD: A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631-634.
-
(2001)
Nat Med
, vol.7
, pp. 631-634
-
-
Butler, S.M.1
Hansen, M.S.2
Bushman, F.D.3
-
14
-
-
0037542551
-
Once-a-day highly active antiretioviral therapy: A systematic review
-
Ena J and Pasquau F: Once-a-day highly active antiretioviral therapy: A systematic review. Clin Infect Dis 2003;36:1186-1190.
-
(2003)
Clin Infect Dis
, vol.36
, pp. 1186-1190
-
-
Ena, J.1
Pasquau, F.2
-
15
-
-
0346992391
-
Nevirapine plus efavirenz plus didanosine: A simple, safe, and effective once-daily regimen for patients with HIV infection
-
Jordan WC, Jefferson R, Yemofio F, et al.: Nevirapine plus efavirenz plus didanosine: A simple, safe, and effective once-daily regimen for patients with HIV infection. Natl Med Assoc 2003;95:1152-1157.
-
(2003)
Natl Med Assoc
, vol.95
, pp. 1152-1157
-
-
Jordan, W.C.1
Jefferson, R.2
Yemofio, F.3
|